Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

TILT Biotherapeutics

Request full access

TILT Bio aims to enable T-cell treatments and immune checkpoint inhibitors with oncolytic viruses, used to boost lymphocytes and immunological checkpoint blocking antibody treatments

Helsinki, FinlandFounded 2013Biotech & Life Sciences

About TILT Biotherapeutics

Developer of a biotechnology platform intended to develop oncolytic immunotherapies that will modify the tumor microenvironment and eliminate its ability to suppress immune responses to cancer. The company's platform involves the utilization of oncolytic viruses for the enhancement of tumor cell therapy and will be used in tumor-infiltrating lymphocytes, chimeric antigen receptors, and checkpoints, enabling researchers to inhibit antibody therapy for solid tumors so as to achieve similar results.

Source: Dealroom company data

At a glance

Status
Operational
Employees
27
Open positions
None listed
Dealroom signal
70.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Immune System, Spinout, Sustainable Development Goals, EIC, Biotech and Pharma, EIC Fund, Nordic Rising Star 2022, Horizon Europe
Business model
Manufacturing
Client focus
B2B

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing May 2025 $25M $99M Lifeline Ventures · Tesi · EIC Fund · Stephen Industries ↗
GRANTOther financing Mar 2024 $0 — European Innovation Council —
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

TILT Biotherapeutics website traffic

Latest recorded traffic for TILT Biotherapeutics is 2.2K monthly website visits, up 29.4% over the last three months. TILT Biotherapeutics's team grew 0% over the past year.

Latest monthly visits2.2K 3-month web change+29.4% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

TILT Biotherapeutics in the Helsinki ecosystem

Live from Dealroom

The TILT Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • European Innovation Council
  • US Department of War

Series A3 investors entered at this stage

Series B and later4 investors entered at this stage

Other known investors1 additional known investor

  • University of Helsinki
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇫🇮 Finland87%
🇺🇸 United States8.7%
🇱🇺 Luxembourg4.3%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about TILT Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See TILT Biotherapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.